Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
Authors:
- Kh. M. DzaurovaKDKh. M. Dzaurova
- Yu. A. YurichevaYYYu. A. Yuricheva
- M. M. BelyaevaMBM. M. Belyaeva
- S. F. SokolovSSS. F. Sokolov
- N. A. MironovaNMN. A. Mironova
- S. P. GolitsynSGS. P. Golitsyn
- O. Yu. KorennovaOKO. Yu. Korennova
- I. M. ZuevaIZI. M. Zueva
- E. A. TurushevaETE. A. Turusheva
- D. S. TerekhovDTD. S. Terekhov
Open Access
- 30 June 2025
- journal article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (2) , 119-125
Abstract
Aim. To evaluate the effectiveness and safety of cavutilide in patients with a history of unsuccessful cardioversion to terminate current persistent and paroxysmal atrial fibrillation (AF) episode.Material and methods. The retrospective study included 55 patients (mean age 60±8 years; male/female ratio 37/18) with paroxysmal (n=15) and persistent (n=40), who had unsuccessfully attempted to terminate the current episode of arrhythmia using electrocardiography. All patients received сavutilide in the intensive care unit according to the following regimen: 5 μg/kg-5 μg/kg-10 μg/kg-10 μg/kg. After each bolus and before the next one, ECG parameters (rhythm, QT interval) and the patients’ general condition were assessed; the interval between administrations was 15 minutes. Administration was halted if sinus rhythm (SR) was restored, heart rate (HR) fell below 50 bpm, QTc exceeded 500 ms, or arrhythmogenic effects occurred. Patients were monitored telemetrically for 24 hours to assess efficacy and safety.Results. SR was restored in 47 (85.4%) out of 55 patients, with a median restoration time of 40 [15-240] minutes. Five patients (9%) achieved SR after the initial of 5 μg/kg dose. Sixteen additional patients responded to 10 μg/kg (cumulative efficacy: 38%). Nine further patients achieved SR at 20 μg/kg (cumulative efficacy: 54.5%). The remaining patients required the maximum 30 μg/kg dose. QTc prolongation >500 ms occurred in 12 (21.8%) patients, though none developed sustained ventricular arrhythmias. Transient HR reduction Conclusion. Cavutilide demonstrates high effectiveness and safety in restoring heart rhythm in patients with prior unsuccessful electrical cardioversion attempts. These findings support considering pharmacological cardioversion with cavutilide in such cases.Keywords
This publication has 8 references indexed in Scilit:
- Ablation therapy following unsuccessful electrical cardioversion in patients with persistent atrial fibrillationScientific Reports, 2024
- Takotsubo syndrome in a patient with atrial fibrillation after electrical cardioversion: a case reportRussian Journal of Cardiology, 2022
- Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years laterCardiovascular Therapy and Prevention, 2021
- 2020 Clinical guidelines for Atrial fibrillation and atrial flutterRussian Journal of Cardiology, 2021
- Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of EffectivenessRational Pharmacotherapy in Cardiology, 2021
- Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experienceClinical and Experimental Emergency Medicine, 2019
- Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart SurveyEP Europace, 2012
- Electrical and Pharmacologic Cardioversion for Atrial FibrillationMedical Clinics of North America, 2008